JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

OBJECTIVE: Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofacitinib and upadacitinib to elucidate the pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Traves, Paqui G, Murray, Bernard, Campigotto, Federico, Galien, René, Meng, Amy, Di Paolo, Julie A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237188/
https://www.ncbi.nlm.nih.gov/pubmed/33741556
http://dx.doi.org/10.1136/annrheumdis-2020-219012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237188/
https://www.ncbi.nlm.nih.gov/pubmed/33741556
http://dx.doi.org/10.1136/annrheumdis-2020-219012

Ejemplares similares